By Fineline Cube 
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) is set to enter into a licensing agreement with US-headquartered Calico Life Sciences LLC regarding its 9MW3811, an anti-IL-11 humanized monoclonal antibody (mAb) being studied in clinical trials for fibrosis and tumors.
Agreement Details
Under the terms of the agreement, Calico will secure exclusive global rights (excluding Greater China) to develop, manufacture, and commercialize 9MW3811. In return, Mabwell will receive an upfront payment of USD 25 million from Calico. Additionally, Mabwell is eligible for milestone payments totaling up to USD 571 million, contingent upon the achievement of specific development, regulatory, and commercial milestones. The agreement also includes provisions for tiered royalties based on the net sales of the product.
Drug Development
9MW3811 is currently undergoing clinical studies in China, Australia, and the US. The drug is being investigated for its potential applications in the treatment of fibrosis and various tumors, with the goal of addressing significant unmet medical needs in these areas.-Fineline Info & Tech